Clinical Study
Repeated Autologous Bone Marrow Transfusion through Portal Vein for Treating Decompensated Liver Cirrhosis after Splenectomy
Table 2
Clinical characteristics of patients.
| | Groups | value | | Control | ABMT |
| | Sex (male, %) | 80% | 60% | >0.05 | | Age (year) | 51.29 ± 11.38 | 45 ± 9.23 | >0.05 | | ALT (U/L) | 30.29 ± 15.84 | 32.42 ± 21.41 | >0.05 | | TB (μmol/L) | 28.51 ± 11.91 | 27.42 ± 20.37 | >0.05 | | PTA (%) | 66.29 ± 9.14 | 56.23 ± 11.27 | >0.05 | | ALB (g/L) | 32.64 ± 5.2 | 32.14 ± 5.46 | >0.05 | | CHE (U/L) | 3065 ± 1661 | 3060 ± 847.9 | >0.05 | | WBC (109/L) | 2.27 ± 0.71 | 2.27 ± 1.60 | >0.05 | | RBC (109/L) | 3.66 ± 0.72 | 3.19 ± 0.55 | >0.05 | | PLT (109/L) | 43.11 ± 24.11 | 44.36 ± 22.01 | >0.05 | | Child–Pugh | 7.44 ± 1.23 | 7.71 ± 1.48 | >0.05 | | LSM (kPa) | 22.25 ± 12.78 | 22.06 ± 13.29 | >0.05 | | AFP (ng/mL) | 3.4 ± 2.66 | 54.68 ± 122.35 | >0.05 |
|
|
AFP: α-fetoprotein; ALB: serum albumin; ALT: alanine aminotransferase; CHE: cholinesterase; LSM: liver stiffness measurement; PLT: platelet; PTA: prothrombin activity; RBC: red blood cell; TB: total bilirubin; WBC: white blood cell. Values are mean ± standard deviation.
|
